Business Context and Reporting Period
The filing is a Form 10-Q for Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), not Spyre Therapeutics, Inc. It covers the three and nine months ended September 30, 2021, and was filed November 4, 2021. Aeglea is a clinical-stage biotechnology company developing engineered human enzyme therapeutics for rare metabolic diseases. Its lead candidate is pegzilarginase for Arginase 1 Deficiency; AGLE-177 is in a Phase 1/2 trial for Homocystinuria.
Key Financial Metrics
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $1.4 million; 2020: $0 | $15.1 million; 2020: $0 |
| Research and development expense | $14.9 million; up 19% | $40.3 million; down 8% |
| General and administrative expense | $6.8 million; up 21% | $20.0 million; up 35% |
| Net loss | $20.3 million; 2020: $18.0 million | $45.4 million; 2020: $58.2 million |
| Net loss per share | $0.31 | $0.69 |
| Net cash used in operating activities | Not separately reported | $34.4 million; 2020: $58.6 million |
Revenue consisted entirely of license and development revenue under the Immedica agreement; the company had no commercial product revenue. Approximate net margins were negative 1,452% for the quarter and negative 301% for the nine-month period, reflecting the company’s pre-commercial development stage.
At September 30, 2021, cash and cash equivalents were $24.7 million, marketable securities were $87.8 million, and restricted cash was $1.8 million. Total liquidity, including cash, cash equivalents, marketable securities and restricted cash, was $114.3 million, with working capital of $97.1 million. Total liabilities were $27.0 million, and the company reported no debt or credit facility. Accumulated deficit was $321.4 million.
Material Changes Versus the Prior Comparable Period
- Revenue increased from zero to $1.4 million in the quarter and $15.1 million for the nine months, primarily from the Immedica license and development agreement.
- Quarterly net loss increased 13% to $20.3 million as operating expenses rose faster than recognized revenue.
- Nine-month net loss decreased 22% to $45.4 million, aided by lower manufacturing costs and the recognition of Immedica-related revenue.
- Nine-month research and development expense declined $3.6 million, primarily because certain pre-commercial pegzilarginase manufacturing activities were completed; clinical and nonclinical development costs increased for PEACE and AGLE-177.
- Nine-month general and administrative expense increased $5.2 million, driven by increased personnel, professional services, legal costs and commercial planning activities.
- Cash used in operations declined by $24.2 million year over year, while investing cash use was $32.3 million and financing cash inflow was only $1.3 million, compared with $129.8 million in the prior-year period from a public offering.
Outlook, Commentary, Risks and Unusual Items
- Management stated that existing cash, cash equivalents and marketable securities should fund operations into 2023, but additional financing will be required to execute all planned research, development and commercialization activities.
- The company expects continuing operating losses and increasing expenditures related to clinical development, manufacturing, potential commercialization of pegzilarginase, pipeline development, personnel and public-company costs.
- The Phase 3 PEACE trial completed screening and randomized 32 patients in April 2021, exceeding the 30-patient target. Topline data were expected in December 2021.
- The company initiated dosing in the AGLE-177 Phase 1/2 trial in June 2021, but COVID-19 and lockdowns in Australia slowed enrollment; management no longer expected to provide a clinical update during 2021.
- Under the March 2021 Immedica agreement, Aeglea received a $21.5 million non-refundable upfront payment, recognized $12.0 million of license revenue and $3.1 million of development revenue through September 30, and recorded $6.4 million of deferred revenue. The agreement also provides potential milestone payments of approximately $130.0 million and royalties in the mid-20% range on net sales in the licensed territories.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, COVID-19 disruptions, reliance on contract manufacturers and research organizations, need for additional capital, potential dilution from equity issuance and outstanding pre-funded warrants, intellectual-property disputes, competition, reimbursement uncertainty and adverse events.
- The company reported no material pending legal proceedings, no off-balance-sheet arrangements and effective disclosure controls at September 30, 2021. Future minimum lease commitments through April 2028 were $7.3 million.
Investor Verification Items
- Verify the issuer identity: the supplied filing is for Aeglea BioTherapeutics, Inc., whereas the request identifies Spyre Therapeutics, Inc.
- Verify subsequent results and regulatory developments for the Phase 3 PEACE trial, including whether the expected December 2021 topline data were delivered and their implications.
- Reconcile the company’s projected cash runway into 2023 with ongoing quarterly cash burn, clinical-trial costs and potential financing needs.
- Review the Immedica agreement’s remaining performance obligations, deferred-revenue release schedule, milestone constraints and royalty economics.
- Assess dilution risk from the 16.6 million outstanding pre-funded warrants, equity compensation and available shelf and at-the-market offering capacity.
- Monitor COVID-19, enrollment, manufacturing, regulatory and safety developments affecting pegzilarginase and AGLE-177.